Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy

NCT01793636 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT01793636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01793636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2013
Completion date
November 30, 2015
Enrollment
49 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal carcinoma